XBP1 and leukemia: Over the course of 6 months Dox treatment, several mice harboring Gata1- or Xbp1-deficient leukemia succumbed to relapse, however overall survival was significantly improved relative to controls (Fig. 7c; p = 0.016 or 0.002, Mantel-Cox test).